US FDA's Patient Affairs Office Is An Office … In Spirit
Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.
You may also be interested in...
Independent assessment finds positive perceptions of expanded access program but calls on agency to do more to correct manufacturer misperceptions about adverse events and clarify when data from expanded access would support labeling extensions.
Reorganization also may force change to commissioner succession plan.
Agency's agreement with rare disease advocacy group will facilitate patient meetings with review divisions, as well as enhance communication of safety information.